NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Janux Therapeutics, Inc. (JANX) Stock Analysis

Janux Therapeutics, Inc. (JANX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

JANX

$16.93

−$0.27 (−1.57%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JANX with… →

JANX Key Statistics

As of Oct 21, 2026
Trading
Open
$17.22
Previous Close
$17.20
Day's Range
16.79–17.47
52-Week Range
12.12–35.34
Volume
587.43K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.39
Valuation
Market Cap
$1.04B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
43.13
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.64
Financials (FY)
Revenue (FY)
$10.00M−5.55%
Net Income (FY)
−$113.63M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.14M
1-Year Return
−36.90%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
847.99K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, JANX closed at $16.93, −36.90% over 1 year.

Janux Therapeutics, Inc. (JANX) has a market capitalization of $1.04B.

In fiscal 2025, JANX reported revenue of $10.00M.

JANX Stock Return by Calendar Year

Janux Therapeutics, Inc. (JANX) return since Jun 2021: what $10,000 became

1 year
$10,000 $6,310
−36.90%
5 years
$10,000 $6,767
−32.33%
Since Jun 2021
$10,000 $6,732
−32.68%

If you had invested $10,000 in Janux Therapeutics, Inc. (JANX) at the close on June 11, 2021, the earliest close on record here, it would have been worth $6,732 at the close on October 21, 2026: −32.68% in total, −7.12% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+22.68%
2025−74.22%
2024+398.97%
2023−18.53%
2022−33.25%
2021 (partial year)−21.55%

As of October 21, 2026.

JANX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$10.00M−$113.63M−1,136.3%
2024$10.59M−$68.99M−651.6%
2023$8.08M−$58.29M−721.2%
2022$8.61M−$63.06M−732.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$10.00M—−$157.67M−$113.63M−1,136.3%
2024$10.59M—−$98.85M−$68.99M−651.6%
2023$8.08M—−$72.98M−$58.29M−721.2%
2022$8.61M—−$67.09M−$63.06M−732.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JANX Valuation vs Biotechnology Median

Median of 608 stocks
MetricJANXBiotechnology medianvs median
P/S ratio43.1313.303.2x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Janux Therapeutics, Inc. (JANX) carries a market capitalisation of $1.04B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 113.

Over the past 52 weeks the price has ranged from $12.12 to $35.34. JANX last closed at $16.93 on October 21, 2026. That is −$0.27 (−1.57%) against the previous close. The latest close sits 39.69% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $10.00M. Against the prior fiscal year total of $10.59M, that is a change of −5.55%. The same year closed with a net loss of $113.63M. Trailing earnings per share are −1.64.

Across the 4 fiscal years on file, revenue moves from $8.61M in 2022 to $10.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 43.13 times revenue. On price-to-sales that is 3.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −36.90%. Measured over 5 years, that is −7.51% a year compounded. The reported beta is 2.39. Annualized volatility over the trailing 5 years is 129.02%.

Growth & Income

The record shows no dividend for JANX.

2026 is still running; the total return is +22.68% year to date. The strongest complete calendar year on file is 2024 at +398.97%; the weakest is 2025 at −74.22%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Janux Therapeutics, Inc. (JANX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Janux Therapeutics, Inc. JANX $1.04B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Janux Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Visit website →